Brief: DBP Reports In Vivo Proof-Of-Concept Study Of SI-053 Was Successfully Finished
16/10/2020 11:25
Oct 16 (Reuters) - Double Bond Pharmaceutical International
AB (publ) DBPHAb.TE :
* SI-053 EFFICACY WAS SUCCESSFULLY PROVEN IN IN VIVO STUDY
IN MICE
* ANIMALS TOLERATED SOC AND SHOWED REDUCED TUMOR VOLUME WHEN
COMPARED TO NON-TREATED ANIMALS
* EFFECT OF SI-053 WAS POTENTIATED WHEN COMBINED WITH SOC,
RESULTING IN 34% OF TUMOR GROWTH INHIBITION
* ALL SI-053 DOSES SHOWED STATISTICALLY SIGNIFICANT
SUPERIORITY IN
REDUCING THE TUMOR VOLUME EVEN BEFORE STARTING THE SOC
Source text for Eikon: ID:
Further company coverage: DBPHAb.TE
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
Recent news on Double Bond Pharmaceutical International AB (publ)
See all newsBrief: DBP International AB And Vivo Biopharma LLC Revised Asset Purchase And Collaboration Agreements
Brief: DBP International AB And Vivo Biopharma LLC Enter Into Asset Purchase And Collaboration Agreements To Develop And Commercialize A Novel Glioblastoma Treatment
Brief: DBP And Vivo Enter Into Asset Purchase And Collaboration Agreements To Develop And Commercialize A Novel Glioblastoma Treatment
Brief: Double Bond Pharmaceutical Says Positive Response For SI-053 From Ethical Committee In Netherlands Has Been Received
Brief: Double Bond To Cooperate With Belarus State Medical University